

CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1–12 (Canceled).

13. (Previously Presented) A method of treating neuralgia pain or neuropathic pain, in a mammal, including a human, comprising administering to a patient in need thereof a therapeutically effective amount of a combination of flupirtine or a therapeutically utilizable salt thereof with a sodium channel-inhibiting or -influencing substance, wherein the sodium channel-inhibiting or influencing substance is selected from the group consisting of tolperisone, eperisone, silperisone, and other tolperisone analogs, and riluzole, propafenone, lidocaine, flecainide and metixen, and their pharmaceutically utilizable salts.

14. (Previously presented) The method of claim 13, wherein the sodium channel-inhibiting or -influencing substance is selected from tolperisone, eperisone, silperisone, and other tolperisone analogs, and their pharmaceutically utilizable salts.

15. (Previously presented) The method of claim 13, where the sodium channel-inhibiting or -influencing substance is selected from eperisone, silperisone, riluzole, propafenone, lidocaine, flecainide, metixen, and their pharmaceutically utilizable salts.

16. (Previously presented) The method of claim 14, wherein the sodium channel-inhibiting or -influencing substances is selected from tolperisone, eperisone, silperisone, and their pharmaceutically utilizable salts.

17. (Withdrawn) The use of flupirtine in combination with tolperisone or its analogs, such as eperisone or silperisone, or their pharmaceutically utilizable salts, for treating pain which is accompanied by an increase in muscle tone.

18. (Withdrawn) The method of claim 13, where the pain is associated with neuralgias.

19. (Withdrawn) The method of claim 13, where the pain is associated with arthritis and arthrosis.

20. (Withdrawn) The method of claim 13, where the pain is associated with chronic or episodic tension headache.

21. (Withdrawn) The method of claim 13, where the pain is associated with lower spastic paraparesis syndrome.

22. (Withdrawn) The method of claim 13, where the pain is associated with lower paraspasm, transverse myelitis, multiple sclerosis, heritable inferior spastic paraplegia (Stuempel paraplegia), disturbances of the spinal blood circulation, or cerebral paralysis involving lower spastic paresis.

23. (Withdrawn) The method of claim 13, where the pain is associated with tetraparesis, in connection with cervical myelopathy, cervical brachialgia or vertebral dysplasia.

24. (Withdrawn) The method of claim 13, where the pain is associated with Parkinson's disease.

25. (Previously presented) The method of claim 13, wherein said sodium channel-inhibiting or -influencing substance or therapeutically utilizable salt thereof is administered simultaneously with flupirtine or a therapeutically utilizable salt thereof.

26. (Previously presented) The method of claim 13, wherein said sodium channel-inhibiting or -influencing substance, or a therapeutically utilizable salt thereof is administered separately or consecutively with flupirtine.

27. (Previously presented) The method of claim 13, wherein said neuralgia pain or neuropathic pain is accompanied by an increase in muscle tone.

28. (Previously presented) The method of claim 27, wherein the sodium channel-inhibiting or -influencing substance is selected from tolperisone, eperisone, silperisone, and other tolperisone analogs, and their pharmaceutically utilizable salts.

29. (Previously presented) The method of claim 27, where the sodium channel-inhibiting or -influencing substance is selected from eperisone, silperisone, riluzole, propafenone, lidocaine, flecainide, metixen, and their pharmaceutically utilizable salts.

30. (Previously presented) The method of claim 28, wherein the sodium channel-inhibiting or -influencing substance is selected from tolperisone, eperisone, silperisone, and their pharmaceutically utilizable salts.